12.12MMarket Cap-0.40P/E (TTM)
0.1990High0.1852Low344.24KVolume0.1892Open0.1911Pre Close66.32KTurnover0.59%Turnover RatioLossP/E (Static)63.78MShares0.620052wk High4.13P/B11.01MFloat Cap0.162852wk Low--Dividend TTM57.94MShs Float836.0000Historical High--Div YieldTTM7.22%Amplitude0.1628Historical Low0.1920Avg Price1Lot Size
AIM ImmunoTech Stock Forum
AIM ImmunoTech Announced It Was Granted Patent No. 2,0832,813 Covering Ampligen For Use In Treatment Of Post-COVID Condition Of Fatigue
AIM ImmunoTech Refutes Activist Group's False and Misleading Claims
2 minutes ago, 12:30 PM PST
Via BusinessWire
Sets Record Straight on Mischaracterization of AIM's Historical Share Price
Reminds AIM Shareholders of Activist Group's Numerous Lies, Omissions and Misrepresentations in Multi-Year Effort to Take Control of the Board
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials Receiv...
2 MINUTES AGO, 3:30 PM EST
VIA BUSINESSWIRE
Sets Record Straight on Mischaracterization of AIM's Historical Share Price
Reminds AIM Shareholders of Activist Group's Numerous Lies, Omissions and Misrepresentations in Multi-Year Effort to Take Control of the Board
Urges Shareholders to Safeguard AIM by Voting "FOR" ALL Four of the Board's Incumbent Candidates and Discarding Any Proxy Materials Received...
4 MINUTES AGO, 8:00 AM EST
VIA GLOBENEWSWIRE
OCALA, Fla., Nov. 19, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that data were published on Roswell Park Comprehensive Cancer Center's Phase 1 study evaluating AIM ImmunoTech's drug Ampligen® (also known as rintatolimod) ...
AIM ImmunoTech | SC 13G: Statement of acquisition of beneficial ownership by individuals-Armistice Capital, LLC(6.84%),Steven Boyd(6.84%)
4 mins ago
AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis
📊⚡️📊
No comment yet